Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9

Benzinga · 2d ago
Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.